Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ONKT101
i
Other names:
ONKT101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Avectas, ONK Therap
Drug class:
CD19 inhibitor, TRAIL R2 agonist
Related drugs:
‹
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
ABBV-621 (3)
AMG 655 (1)
INBRX-109 (1)
BI 905711 (0)
CPT (0)
CTB-006 (0)
DS-8273 (0)
TLY012 (0)
IGM-8444 (0)
RG7425 (0)
AMG 951 (0)
CS-1008 (0)
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
ABBV-621 (3)
AMG 655 (1)
INBRX-109 (1)
BI 905711 (0)
CPT (0)
CTB-006 (0)
DS-8273 (0)
TLY012 (0)
IGM-8444 (0)
RG7425 (0)
AMG 951 (0)
CS-1008 (0)
›
Associations
News
Trials
Filter by
Latest
over3years
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
Finally, we consider the broader landscape of competing immunotherapeutic approaches to AML treatment. In doing so we evaluate the innate potential, status and remaining barriers for CAR-NK based AML immunotherapy.
over 3 years ago
Review • Journal
|
CD19 (CD19 Molecule)
|
ONKT101
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login